Differences in the impact of newly diagnosed type 2 diabetes on cardiovascular mortality between normotensive and hypertensive individuals

被引:1
|
作者
Sasaki, Nobuo [1 ,2 ]
Maeda, Ryo [1 ]
Ozono, Ryoji [3 ]
Yoshimura, Kenichi [4 ]
Nakano, Yukiko [5 ]
Higashi, Yukihito [2 ]
机构
[1] Hiroshima Atom Bomb Casualty Council, Hlth Management & Promot Ctr, 3-8-6 Senda machi,Naka ku, Hiroshima 7300052, Japan
[2] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Regenerat Med, Hiroshima, Japan
[3] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gen Med, Hiroshima, Japan
[4] Hiroshima Univ Hosp, Med Ctr Translat & Clin Res, Dept Biostat, Hiroshima, Japan
[5] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima, Japan
关键词
cardiovascular mortality; heart failure; hypertension; prediabetes; type; 2; diabetes; RISK-FACTORS; OXIDATIVE STRESS; GLUCOSE CONTROL; HEART-FAILURE; DISEASE; MELLITUS; OUTCOMES; COMPLICATIONS; INFLAMMATION; DEATH;
D O I
10.1097/HJH.0000000000003671
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: We investigated the interrelationship between hyperglycemia and hypertension on cardiovascular mortality in the middle-aged and elderly people. Methods: In this retrospective cohort study that used data from the Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases, we included 16,564 participants without cardiovascular disease (mean age: 65.8 years; 6179 normoglycemic people, 3017 people with newly diagnosed type 2 diabetes, and 7368 people with prediabetes per the 75-g oral glucose tolerance test). Hypertension was defined as the use of antihypertensive medications and/or having a systolic/diastolic blood pressure of at least 140/90 mm Hg. Results: During a median follow-up period of 12.4 years, a total of 1513 cardiovascular death occurred. Cardiovascular death rates per 1000 participant-years were 4.01, 4.98, 8.33, 8.22, 8.81, and 11.1 among normotensive participants with normal glycemia, prediabetes, and diabetes and hypertensive participants with normal glycemia, prediabetes, and diabetes, respectively. Prediabetes was significantly associated with a high risk of cardiovascular mortality in normotensive individuals [hazard ratio: 1.24, 95% confidence interval (95% CI): 1.02-1.50] but not in hypertensive individuals. Type 2 diabetes was associated with a high risk of cardiovascular mortality in both normotensive (hazard ratio: 1.94, 95% CI: 1.55-2.43) and hypertensive individuals (hazard ratio: 1.35, 95% CI: 1.13-1.62). Stratified analyses revealed no significant impact of type 2 diabetes on cardiovascular mortality in hypertensive individuals aged at least 65 years. Conclusion: The effect of hyperglycemia on cardiovascular death differed with age and the presence or absence of hypertension, demonstrating the clinical importance of case-specific risk assessments.
引用
收藏
页码:610 / 619
页数:10
相关论文
共 50 条
  • [41] Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
    Rawshani, Aidin
    Rawshani, Araz
    Franzen, Stefan
    Eliasson, Bjorn
    Svensson, Ann-Marie
    Miftaraj, Mervete
    McGuire, Darren K.
    Sattar, Naveed
    Rosengren, Annika
    Gudbjornsdottir, Soffia
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (15) : 1407 - 1418
  • [42] Impact of hypoglycemia at the time of hospitalization for heart failure from emergency department on major adverse cardiovascular events in patients with and without type 2 diabetes
    Cha, Seon-Ah
    Yun, Jae-Seung
    Kim, Gee-Hee
    Ahn, Yu-Bae
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [43] Relationship between degree of risk factor control and all-cause mortality in individuals with type 2 diabetes: A prospective cohort study
    Garofolo, Monia
    Penno, Giuseppe
    Solini, Anna
    Orsi, Emanuela
    Vitale, Martina
    Resi, Veronica
    Bonora, Enzo
    Fondelli, Cecilia
    Trevisan, Roberto
    Vedovato, Monica
    Nicolucci, Antonio
    Pugliese, Giuseppe
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 128 : 53 - 62
  • [44] Inverse Association of Plasma Chromium Levels with Newly Diagnosed Type 2 Diabetes: A Case-Control Study
    Chen, Sijing
    Jin, Xiaoling
    Shan, Zhilei
    Li, Shuzhen
    Yin, Jiawei
    Sun, Taoping
    Luo, Cheng
    Yang, Wei
    Yao, Ping
    Yu, Kaifeng
    Zhang, Yan
    Cheng, Qian
    Cheng, Jinquan
    Bao, Wei
    Liu, Liegang
    NUTRIENTS, 2017, 9 (03):
  • [45] Empagliflozin Reduces the Risk of Mortality, Macro- and Microvascular Events in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Seufert, Jochen
    Galle, Jan-Christoph
    Manning, Martina
    Schmid, Volkmar
    Lehrke, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (04) : 294 - 306
  • [46] Influence of dapagliflozin on cardiovascular remodeling in hypertensive patients with accompanying type 2 diabetes
    Bohun, A. O.
    PATHOLOGIA, 2024, 21 (01): : 41 - 50
  • [47] A 12-year follow-up study of all-cause and cardiovascular mortality among 10 532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland
    Barnett, K. N.
    Ogston, S. A.
    McMurdo, M. E. T.
    Morris, A. D.
    Evans, J. M. M.
    DIABETIC MEDICINE, 2010, 27 (10) : 1124 - 1129
  • [48] All-cause Mortality and Incidence of Cardiovascular Diseases in Lean Patients With Newly Diagnosed Type 2 Diabetes
    Song, Do Kyeong
    Oh, Jongmin
    Sung, Yeon-Ah
    Hong, Young Sun
    Lee, Hyejin
    Ha, Eunhee
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025, 110 (05) : e1547 - e1554
  • [49] Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes
    Geng, Tingting
    Chen, Jun-Xiang
    Zhou, Yan-Feng
    Lu, Qi
    Wan, Zhenzhen
    Liu, Liegang
    Pan, An
    Liu, Gang
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (06) : E216 - E222
  • [50] Factors associated with stroke, myocardial infarction, ischemic heart disease, unstable angina, or mortality in patients from real world clinical practice with newly-diagnosed type 2 diabetes and early glycemic control
    Alatorre, Carlos I.
    Hoogwerf, Byron J.
    Deeg, Mark A.
    Nelson, David R.
    Hunter, Theresa M.
    Ng, Wee Teck
    Rekhter, Mark D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (02) : 337 - 343